Evidence map›Paper›PMID 29951735›Full record

Trial reportInternational journal of hematology2018

Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates.

Inaam Bashir Hassan, Jorgen Kristensen, Khalid Al Qawasmeh, Arif Alam

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Inaam Bashir HassanDepartment of Internal Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates. inaambh@uaeu.ac.ae.
Jorgen KristensenMediclinic North Wing, Dubai, United Arab Emirates.
Khalid Al QawasmehDepartment of Hematology, Oncology Tawam Hospital, Al Ain, United Arab Emirates.
Arif AlamDepartment of Hematology, Oncology Tawam Hospital, Al Ain, United Arab Emirates.
Tawam Hospital · AEMediclinic City Hospital · AEUnited Arab Emirates University · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the outcome of 47 adult patients with relapsed acute leukaemia (AML = 25 and ALL = 22) treated with FLAG-mitoxantrone regimen. Median time to relapse was 10.7 months (range 1.9-27.7). Complete remission (CR2) was 60.1% which was significantly more frequent in ALL compared to AML (P = 0.049). WBC count < 100 × 10

Indexed as

Induction ChemotherapyAcute DiseaseAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCytarabineDisease-Free SurvivalFemaleGranulocyte Colony-Stimulating FactorHumansLeukemiaMaleMiddle AgedMitoxantroneRecurrenceCytarabineGranulocyte Colony-Stimulating FactorMitoxantroneVidarabineALLAMLFLAG–mitoxantroneRe-inductionRelapse

Identifiers

PMID29951735
OpenAlexW2811159758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.